Why Is Trulieve Cannabis (TRLV) Stock Down -13.54% Today?
Key Takeaways
- Shares of Trulieve Cannabis Corp. tumbled roughly 13.5% in Wednesday's session, with the stock trading near $10.73 versus a prior close of $12.41.
- Primary catalyst: a DEA administrative judge paused the broader federal cannabis rescheduling case, delaying a decision investors had treated as a near-term catalyst.
- Secondary driver: a "sell-the-news" reaction to Monday's exclusive master licensing agreement with Connected Cannabis covering the Alien Labs and Connected brands in Florida and Texas.
- Sector pressure: the AdvisorShares Pure US Cannabis ETF (MSOS) slid roughly 8% after hours, dragging peers including TRLV lower.
- Technical context: the decline follows a strong run that left the stock up more than 40% year-to-date and its relative strength indicator in overbought territory.
- What to watch next: the DEA process timeline, upcoming third-quarter results, and broader cannabis-sector sentiment.
Opening Summary
Trulieve Cannabis Corp. (TRLV), a vertically integrated U.S. multi-state medical cannabis operator and the first plant-touching U.S. cannabis company to list on the New York Stock Exchange, saw its shares drop sharply on Wednesday. The stock fell approximately 13.5%, trading near $10.73 during the session after closing the prior completed session at $12.41. The move marks a decisive reversal of recent gains and reflects a confluence of regulatory, corporate, and sentiment-driven headwinds rather than a single fundamental shock.
DEA Pause on Cannabis Rescheduling Weighs on the Sector
The most immediate trigger for the selloff was a regulatory development. DEA Chief Administrative Law Judge Derek Julius paused the pending case on whether to move the remainder of marijuana — including adult-use product — from Schedule I to Schedule III under the Controlled Substances Act. The hearing concluded in mid-July, and investors had widely expected a recommendation to the DEA administrator to follow. That step is now on hold while the judge weighs whether to reopen the record to incorporate a recent Government Accountability Office report on drug-scheduling procedures.
The pause does not reject rescheduling, nor does it cancel the earlier Schedule III reclassification of state-licensed medical marijuana that took effect in April. However, it delays a decision the market had priced as a meaningful catalyst for the broader cannabis industry. As one of the sector's most prominent names, TRLV bore the brunt of the resulting repricing, with cannabis-focused funds such as MSOS also falling sharply.
Sell-the-News Reaction to the Connected Licensing Deal
Compounding the regulatory setback, investors appeared to digest the company's September 28 announcement of an exclusive master licensing agreement with Connected Cannabis. The perpetual, royalty-free deal grants TRLV rights to the genetics, trademarks, and proprietary know-how for the premium Alien Labs and Connected brands in Florida and Texas. While strategically significant, the agreement introduces near-term integration, marketing, and execution costs, prompting some traders to reassess the short-term financial impact and lock in profits after a strong run.
Profit-Taking After an Extended Rally
The decline also reflects positioning rather than a shift in the fundamental view of Wall Street analysts. TRLV entered the week up more than 40% for the year, boosted by its June NYSE uplisting, the medical-marijuana rescheduling milestone, its addition to the S&P Total Market and S&P Completion Indices, and progress on DEA registrations for its medical operations. With the stock's relative strength index having recently exited overbought territory, the regulatory delay gave traders an opportunity to reduce exposure, resulting in an outsized downward move.
Market Context and Trading Activity
The decline in TRLV was accompanied by elevated trading activity and a sector-wide pullback, with cannabis ETFs and peers moving in sympathy. Broader equity indices were largely flat to slightly lower during the session, offering no supportive backdrop for riskier, sentiment-sensitive cannabis names. The stock's slide pushed it well below its recent trading range, underscoring how quickly positioning can unwind in a sector whose outlook remains tightly linked to federal regulatory headlines.
What Comes Next for TRLV
Investors will now focus on the timeline for the DEA rescheduling case, including responses due from the government by mid-October, and any signals on whether the record will be reopened. The company's next quarterly earnings report, expected in November, will be closely watched for updates on revenue trends, the integration of the Connected brand partnership, and progress on its Florida and Texas expansion plans. Risks include continued volatility tied to federal cannabis policy, insider selling, and a flat-to-declining revenue outlook even as the company generates strong cash flow and maintains healthy margins. The balance between long-term regulatory upside and near-term execution uncertainty is likely to keep the stock sensitive to headlines in the weeks ahead.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, each with distinct strategies, timeframes, performance metrics, and traded symbols. Only the strongest performers under current market conditions are featured in the curated Trending AI Robots section, helping traders identify strategies that are adapting well to today's market environment. Explore the page to see which AI-driven approaches are currently leading the pack.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Aroon Indicator for TRLV shows an upward move is likely
TRLV's Aroon Indicator triggered a bullish signal on September 29, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 140 similar instances where the Aroon Indicator showed a similar pattern. In 120 of the 140 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +1.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRLV advanced for three days, in 190 of 238 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The 10-day RSI Indicator for TRLV moved out of overbought territory on September 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 26 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TRLV as a result. In 76 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for TRLV turned negative on September 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In 26 of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. TRLV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.096) is normal, around the industry mean (43.873). P/E Ratio (120.482) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.470) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.947) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement